About 100 reports

  • GLOBAL REGENERATIVE MEDICINE MARKET BY OTHER APPLICATIONS

Approximately ##% of clinical trials of regenerative medicine are being conducted in oncology indications such as leukemia, lymphoma, brain cancer, breast cancer, bladder cancer, cervix cancer, colon cancer, esophageal cancer, ovarian

  • Regenerative Medicine
  • Medtronic, Inc.
  • MiMedx Group, Inc.
  • Organogenesis, Inc.
  • Zimmer Biomet Holdings, Inc.
  • CAR-T Cell Therapies in Phase II or Above for Solid Tumors

Clinical Targets Being Investigated for CAR Cell Therapies in Solid Tumors by Organ Group KEY TARGETS ARE EMERGING FOR CERTAIN CANCER TYPES, WITH IMPORTANT TARGETS IN OTHER CANCERS NOT SO WELL DEFINED EPCAM CD## Mesothelin Multiple PSMA FOLR## MET MUC## DLLR## PMEL Source: GlobalDat

  • Regenerative Medicine
  • United States
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG
  • GENE TRANSFER

Larger studies are being conducted for the treatment of rectal, esophageal, pancreatic cancer, and melanoma.

  • Regenerative Medicine
  • Therapy
  • Forecast
  • Market Size
  • Celgene Corporation

CRISPR Edited cells might cause cancer.

  • Regenerative Medicine
  • Casebia Therapeutics LLP
  • Editas Medicine, Inc.
  • Novartis AG
  • Pfizer Inc.
  • TBI-1501 / CD19 CAR-T
  • 14. MARKET SIZING AND OPPORTUNITY ANALYSIS

Therapy PHASE I / II ## LCAR-B##M CAR-T PHASE I / II T-CELL THERAPY (CAR-T) PHASE I / II LENTIVIRAL Indication R/ R CD-##+ CHRONIC LYMPHOCYTIC LEUKEMIA R/ R CD-##+ CHRONIC LYMPHOCYTIC LEUKEMIA RELAPSE AND REFRACTORY MULTIPLE MYELOMA SYNOVIAL SARCOMA (NY-ESO- ##+) SYNOV

  • Regenerative Medicine
  • Market Size
  • Supply
  • Lonza Group Ltd
  • Sanofi S.A.

Gene therapy is emerging as one of the most exciting approaches for the treatment of ovarian cancer.

  • Regenerative Medicine
  • Therapy
  • United States
  • Celsion Corporation
  • Takara Bio Inc.
  • 8.2 TABLE OF ALL PIPELINE PRODUCTS

Cancer; ##(##): ##.

  • Regenerative Medicine
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG

The drug candidate is in Phase II stage for the treatment of squamous and non-squamous non-small cell lung cancer, esophageal cancer, cholangiocarcinoma gastric cancer and FGFR mutation hormone-sensitive breast cancer.

  • Cancer
  • Regenerative Medicine
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

IN ADDITION, LUMMY HK ACQUIRED THE RIGHTS TO DEVELOP PRODUCTS BASED ON THE ARCELIS PLATFORM FOR ADDITIONAL ONCOLOGICAL INDICATIONS, INCLUDING GASTRIC CANCER, ESOPHAGEAL CANCER, RECTAL CANCER, LUNG CANCER, LIVER CANCER, STOMACH CANCER AND PANCREAT

  • Regenerative Medicine
  • North America
  • United States
  • Argos Therapeutics, Inc.
  • Lonza Group Ltd

Magnetic-Targeted Doxorubicin in Treating Patients with Cancer Metastatic to the Liver GDCT## NCT##, MTC-DOX-##; NCT## Oncology Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastroin

  • Chemotherapy
  • Clinical Trial
  • Hepatitis
  • Regenerative Medicine
  • World
  • Target
  • CLINICAL TRIAL PROFILE SNAPSHOTS

CLINICAL TRIALS BY PHASE IN E## COUNTRIES THYROID CANCER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2020* THYROID CANCER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2020* THYROID CANCER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2020* Source:

  • Clinical Trial
  • Drug Development
  • Regenerative Medicine
  • Therapy
  • Eisai Co., Ltd.

COLORECTAL CANCER, NEUROBLASTOMA, OVARIAN, HEAD AND NECK, ESOPHAGEAL AND METASTATIC BREAST CANCER.

  • Cancer
  • Regenerative Medicine
  • North America
  • United States
  • Product Initiative
  • Clinical Trial profile. 484 Trial Title

Infusion GDCT## GDC##, Oncology Metastatic Breast Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Small-Cell Lung Cancer Planned Phase IV Interventional atezolizumab Chugai Pharmaceut

  • Clinical Trial
  • Drug Development
  • Regenerative Medicine
  • Therapy
  • World

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## ## ## Eisai Co Ltd ## ## ## ##

  • Chemotherapy
  • Clinical Trial
  • Regenerative Medicine
  • United States
  • World

CLINICAL TRIALS BY PHASE IN E## COUNTRIES SALIVARY GLAND CANCER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2020* SALIVARY GLAND CANCER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2020* SALIVARY GLAND CANCER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY

  • Cell Therapy
  • Regenerative Medicine
  • Therapy
  • World
  • Product Initiative

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR THE TREATMENT OF SQUAMOUS AND NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, ESOPHAGEAL CANCER, CHOLANGIOCARCINOMA, AND GASTRIC CANCER.

  • Cancer
  • Regenerative Medicine
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

It was also under development for the treatment of colorectal, metastatic prostate cancer, bone metastasis, transitional cell cancer, germ cell tumors, ovarian cancer and esophageal cancer.

  • Cancer
  • Lung Cancer
  • Regenerative Medicine
  • Therapy
  • Geron Corporation

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## Eli Lilly and Co ## ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ##

  • Immunotherapy
  • Regenerative Medicine
  • United States
  • World
  • Product Initiative

The drug candidate is in Phase II stage for the treatment of squamous and non-squamous non-small cell lung cancer, esophageal cancer, cholangiocarcinoma, gastric cancer and advanced hepatocellular carcinoma (HCC).

  • Cancer
  • Regenerative Medicine
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

Magnetic-Targeted Doxorubicin in Treating Patients with Cancer Metastatic to the Liver GDCT## NCT##, MTC-DOX-##; NCT## Oncology Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastroin

  • Clinical Trial
  • Lung Cancer
  • Regenerative Medicine
  • Therapy
  • Novartis AG

Cancer, Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Cancer, Brain Tumor, Breast Cancer, Carcinoid Tumor, Carcinomas, Central Nervous System (CNS) Cancer, Cervical Cancer, Chondrosarcoma, Chronic Myelocytic Leukemia (

  • Clinical Trial
  • Monoclonal Antibody
  • Regenerative Medicine
  • Therapy
  • Novartis AG

## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## ## France Source: Global

  • Cancer
  • Pharmaceutical
  • Regenerative Medicine
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Monoclonal Antibody
  • Regenerative Medicine
  • United States
  • World
  • Product Initiative

## ## Official Title Target Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Biomarker(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Collaborator(s) Estimated Start Date Estimated Completion Date #

  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • Regenerative Medicine
  • World
  • Clinical Trial profile. 373 Trial Title
  • Clinical Trial profile. 309 Trial Title

Magnetic-Targeted Doxorubicin in Treating Patients with Cancer Metastatic to the Liver GDCT## NCT##, MTC-DOX-##; NCT## Oncology Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastroin

  • Clinical Trial
  • Hepatitis
  • Regenerative Medicine
  • Therapy
  • World

## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## AlfaSigma SpA ACTIAL Farmaceutica SA AstraZeneca Plc Arjuna Natural Extracts Ltd ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ARCA biopharma Inc ## ## ## ## Amgen Inc

  • Clinical Trial
  • Hospital
  • Regenerative Medicine
  • Therapy
  • Alizyme plc

The prominent features of this report are - ##.

  • Pharmaceutical
  • Regenerative Medicine
  • Therapy
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Pharmaceutical
  • Regenerative Medicine
  • World
  • Product Initiative

The drug candidate is in Phase II stage for the treatment of squamous and non-squamous non-small cell lung cancer, esophageal cancer, cholangiocarcinoma gastric cancer and FGFR mutation hormone-sensitive breast cancer.

  • Regenerative Medicine
  • Therapy
  • United States
  • Product Initiative
  • Eisai Co., Ltd.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Immunotherapy
  • Regenerative Medicine
  • Therapy
  • World
  • Product Initiative